Publications by authors named "Bruce W S Robinson"

83Publications

Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.

Cancer Epidemiol Biomarkers Prev 2020 Oct 30;29(10):1973-1982. Epub 2020 Jul 30.

James Thoracic Center, James Cancer Center, The Ohio State University Medical Center, Columbus, Ohio.

View Article and Find Full Text PDF
October 2020

Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome.

Oncoimmunology 2020 7;9(1):1684714. Epub 2019 Nov 7.

National Centre for Asbestos Related Diseases, University of Western Australia, Nedlands, Australia.

View Article and Find Full Text PDF
November 2019

Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma.

Oncoimmunology 2020 3;9(1):1684713. Epub 2019 Nov 3.

National Centre for Asbestos Related Disease, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Australia.

View Article and Find Full Text PDF
November 2019

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

J Thorac Oncol 2018 09;13(9):1269-1283

Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. Electronic address:

View Article and Find Full Text PDF
September 2018

Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.

Lung Cancer 2018 05 9;119:64-70. Epub 2018 Mar 9.

National Centre for Asbestos Related Disease, University of Western Australia, Nedlands, Western Australia, 6009, Australia. Electronic address:

View Article and Find Full Text PDF
May 2018

Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.

BMC Cancer 2017 06 2;17(1):396. Epub 2017 Jun 2.

National Centre for Asbestos Related Disease, School of Medicine and Pharmacology, QEII Medical Centre, University of Western Australia, QQ Block, 6 Verdun Street, Nedlands, WA, 6009, Australia.

View Article and Find Full Text PDF
June 2017

A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

Cancer Genomics Proteomics 2017 Mar-Apr;14(2):103-117

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia.

View Article and Find Full Text PDF
April 2017

Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.

Chest 2017 07 19;152(1):143-149. Epub 2016 Dec 19.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA, Australia; Department of Respiratory Medicine, Nedlands, WA, Australia.

View Article and Find Full Text PDF
July 2017

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies.

Chest 2017 Apr 18;151(4):891-897. Epub 2016 Oct 18.

National Centre of Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia; Perth, Western Australia, Australia; Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

View Article and Find Full Text PDF
April 2017

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.

Sci Rep 2016 09 8;6:32643. Epub 2016 Sep 8.

Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria 3086, Australia.

View Article and Find Full Text PDF
September 2016

Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.

Biomarkers 2016 Sep 24;21(6):551-61. Epub 2016 Mar 24.

g National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia , Perth , Western Australia , Australia ;

View Article and Find Full Text PDF
September 2016

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms.

Clin Proteomics 2016 22;13. Epub 2016 Feb 22.

National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia ; School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.

View Article and Find Full Text PDF
February 2016

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms.

Clin Proteomics 2016 22;13. Epub 2016 Jan 22.

National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia ; School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.

View Article and Find Full Text PDF
January 2016

Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma.

BMC Cancer 2015 Dec 18;15:983. Epub 2015 Dec 18.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, M503, Harry Perkins Institute for Medical Research, QQ Block, QEII Medical Centre, Nedlands, Perth, 6009, Western Australia, Australia.

View Article and Find Full Text PDF
December 2015

Discovery of new biomarkers for malignant mesothelioma.

Curr Pulmonol Rep 2015;4(1):15-21

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, 35 Stirling Hwy, Crawley, 6009 Australia ; Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Verdun Ave, Nedlands, 6009 Western Australia Australia.

View Article and Find Full Text PDF
January 2015

Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.

Gene 2015 May 18;563(1):103-5. Epub 2015 Mar 18.

National Centre for Asbestos Related Disease, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia 6009, Australia. Electronic address:

View Article and Find Full Text PDF
May 2015

Author's response: Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies.

Thorax 2015 Apr 5;70(4):374-5. Epub 2014 Dec 5.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia The Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

View Article and Find Full Text PDF
April 2015

Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.

Eur J Immunol 2015 Jan 15;45(1):49-59. Epub 2014 Dec 15.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, The University of Western Australia, Nedlands, WA, Australia.

View Article and Find Full Text PDF
January 2015

Neoadjuvant anti-tumor vaccination prior to surgery enhances survival.

J Transl Med 2014 Sep 4;12:245. Epub 2014 Sep 4.

School of Medicine & Pharmacology, University of Western Australia, Perth, 4th Floor, G Block, Queen Elizabeth II Medical Centre, Perth 6009, WA, Australia.

View Article and Find Full Text PDF
September 2014

Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort.

Lung Cancer 2014 Oct 18;86(1):29-34. Epub 2014 Aug 18.

National Centre for Asbestos Related Diseases, University of Western Australia, Harry Perkins Institute for Medical Research, Nedlands, Perth, 6009 Western Australia, Australia.

View Article and Find Full Text PDF
October 2014

Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans.

PLoS One 2014 5;9(8):e103025. Epub 2014 Aug 5.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Harry Perkins Institute for Medical Research, Nedlands, Perth, Western Australia, Australia.

View Article and Find Full Text PDF
April 2015

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

Thorax 2014 Oct 18;69(10):895-902. Epub 2014 Jul 18.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia The Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

View Article and Find Full Text PDF
October 2014

Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.

Dis Markers 2013 6;35(2):119-27. Epub 2013 Aug 6.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia and Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia.

View Article and Find Full Text PDF
June 2014

Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.

Lung Cancer 2013 Dec 9;82(3):491-8. Epub 2013 Oct 9.

National Centre for Asbestos Related Diseases, University of Western Australia, School of Medicine and Pharmacology, Nedlands, Western Australia, Australia; The Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. Electronic address:

View Article and Find Full Text PDF
December 2013

Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model.

J Immunother 2013 Sep;36(7):365-72

Tumour Immunology Group, School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia.

View Article and Find Full Text PDF
September 2013

Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?

Lung Cancer 2013 Apr 26;80(1):39-44. Epub 2013 Jan 26.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6009, Australia.

View Article and Find Full Text PDF
April 2013

Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation.

Oncoimmunology 2012 Sep;1(6):840-846

School of Medicine and Pharmacology; The University of Western Australia; Crawley, Australia ; National Centre for Asbestos Related Diseases; The University of Western Australia; Crawley, Australia.

View Article and Find Full Text PDF
September 2012

The use of agonistic anti-CD40 therapy in treatments for cancer.

Int Rev Immunol 2012 Aug;31(4):246-66

School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.

View Article and Find Full Text PDF
August 2012

IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.

Int Immunol 2012 Jun 21;24(6):357-68. Epub 2012 Feb 21.

Immunology and Cancer Group, School of Biomedical Sciences, Curtin University, Bentley, Perth, Western Australia, 6102.

View Article and Find Full Text PDF
June 2012

Auto-antibodies to β-F1-ATPase and vimentin in malignant mesothelioma.

PLoS One 2011 17;6(10):e26515. Epub 2011 Oct 17.

National Centre for Asbestos Related Diseases, University of Western Australia, School of Medicine and Pharmacology, Nedlands, Western Australia, Australia.

View Article and Find Full Text PDF
February 2012

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?

Lung Cancer 2011 Oct 12;74(1):55-60. Epub 2011 Mar 12.

National Research Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, 4th Floor, G Block, Verdun St, Nedlands, WA 6009, Australia.

View Article and Find Full Text PDF
October 2011

Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.

Lung Cancer 2011 Sep 18;73(3):320-4. Epub 2011 Feb 18.

University of Western Australia, School of Medicine and Pharmacology, Verdun Street, Nedlands, WA 6009, Australia.

View Article and Find Full Text PDF
September 2011

Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.

Clin Cancer Res 2011 Mar 21;17(5):1181-9. Epub 2010 Dec 21.

National Research Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

View Article and Find Full Text PDF
March 2011

Tumor antigen cross-presentation and the dendritic cell: where it all begins?

Clin Dev Immunol 2010 13;2010:539519. Epub 2010 Oct 13.

School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6009, Australia.

View Article and Find Full Text PDF
February 2011

Sensitivity of urinary mesothelin in patients with malignant mesothelioma.

J Thorac Oncol 2010 Sep;5(9):1461-6

National Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia.

View Article and Find Full Text PDF
September 2010

Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.

Cancer Epidemiol Biomarkers Prev 2010 Sep 22;19(9):2238-46. Epub 2010 Jul 22.

National Research Centre for Asbestos Related Disease, Sir Charles Gairdner Hospital, 2School of Medicine and Pharmacology, University of Western Australia, QEII Medical Centre, Nedlands, Western Australia, Australia.

View Article and Find Full Text PDF
September 2010

Cross-priming in health and disease.

Nat Rev Immunol 2010 Jun;10(6):403-14

Institutes of Molecular Medicine and Experimental Immunology, University Clinic of the Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.

View Article and Find Full Text PDF
June 2010

Scientists appeal to Quebec Premier Charest to stop exporting asbestos to the developing world.

Authors:
Tim K Takaro Devra Davis Sue Janse Van Rensburg Ruth Sara Arroyo Aguilar Eduardo Algranti John C Bailar Fiorella Belpoggi Mathis Berlin Shelley Bhattacharya Y V Bonnier Viger James Brophy Ray Bustinza Robert B Cameron John M Dement David Egilman Barry Castleman Sanjay Chaturvedi Martin Cherniack Harlal Choudhury Paul A Demers Joseph Digangi Ana Digon John G Edwards Anders Englund Bjørn Erikson Heleno Rodrigues Corréa Filho Giuliano Franco Arthur L Frank Alice Freund David Gee Antonio Giordano Michael Gochfeld Marcel Gilberg David F Goldsmith Bernard D Goldstein Philippe Grandjean Morris Greenberg Ivan Gut Raul Harari Marc Hindry Christer Hogstedt James Huff Peter F Infante Bengt Järvholm David G Kern Matthew Keifer Kapil Khatter Helge Kjuus Margaret Keith Linda C Koo Arun Kumar Joseph LaDou Philip J Landrigan Richard A Lemen John M Last Christopher W Lee James Leigh Stephen M Levin Abby Lippman Guadalupe Aguilar Madrid Jock McCulloch Melissa A McDiarmid James A Merchant Celeste Monforton Tim Morse David C F Muir Debdas Mukerjee Karen B Mulloy J Myers Iman Nuwayhid Peter Orris David Ozonoff Domyung Paek Manomita Patra Daniela Pelclová Lew Pepper Gerald V Poje Qamar Rahman Bernardo Reyes Bruce W S Robinson Eduardo Rodríguez Cecile Rose Kenneth D Rosenman Linda Rosenstock Mathuros Ruchirawat Konrad Rydzyński Joachim Schneider Barbara Silverstein C Eduardo Siqueira Craig Slatin Morando Soffritti Colin Soskoline Judy Sparer Leslie Thomas Stayner Tim K Takaro Stanislaw Tarkowski Daniel Thau Teitelbaum Anna Tompa Ivancica Trosic Fernand Turcotte Rodolfo A G Vilela Yvonne R K Waterman Andrew Watterson David H Wegman Laura S Welch Hans-Joachim Woitowitz Zulmiar Yanri Cecillia Zavariz

Int J Occup Environ Health 2010 Apr-Jun;16(2):241-8

View Article and Find Full Text PDF
June 2010

CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor.

Eur J Immunol 2010 Jun;40(6):1617-27

School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia.

View Article and Find Full Text PDF
June 2010

Serum and pleural fluid biomarkers for mesothelioma.

Curr Opin Pulm Med 2009 Jul;15(4):366-70

National Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, University of Western Australia, 4th Floor, G block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia.

View Article and Find Full Text PDF
July 2009

Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy.

Cancer Immunol Immunother 2009 Aug 4;58(8):1219-28. Epub 2008 Dec 4.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.

View Article and Find Full Text PDF
August 2009

Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.

Int Immunol 2008 Nov 29;20(11):1467-79. Epub 2008 Sep 29.

School of Biomedical Sciences, Curtin University, Kent St Bentley, Perth, Western Australia 6102, Australia.

View Article and Find Full Text PDF
November 2008

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.

J Thorac Oncol 2008 Aug;3(8):851-7

National Research Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia.

View Article and Find Full Text PDF
August 2008

Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors.

J Immunol 2008 Feb;180(3):1535-44

National Research Centre for Asbestos Related Diseases, QEII Medical Centre, Verdun Street, Nedlands, Perth 6009, Western Australia.

View Article and Find Full Text PDF
February 2008

Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.

Chest 2007 Oct 23;132(4):1239-46. Epub 2007 Jul 23.

National Research Centre for Asbestos Related Diseases, 4th Floor, G Block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia.

View Article and Find Full Text PDF
October 2007

Soluble mesothelin related protein in mesothelioma.

J Thorac Oncol 2006 Feb;1(2):172-4

School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Wedlands, WA, Australia.

View Article and Find Full Text PDF
February 2006

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.

Thorax 2007 Jul 13;62(7):569-76. Epub 2007 Mar 13.

Department of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Verdun Ave, Nedlands 6009, Western Australia, Australia.

View Article and Find Full Text PDF
July 2007

A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent.

Cancer Res 2006 Nov;66(22):10786-94

School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, Perth, Australia.

View Article and Find Full Text PDF
November 2006

Combined chemoimmunotherapy of solid tumours: improving vaccines?

Adv Drug Deliv Rev 2006 Oct 15;58(8):975-90. Epub 2006 Aug 15.

Department of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, 4th Floor, G block, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009 Australia.

View Article and Find Full Text PDF
October 2006

A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.

Clin Cancer Res 2006 Sep;12(17):5129-35

Ian Potter Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia.

View Article and Find Full Text PDF
September 2006

Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity.

Cancer Res 2006 Jan;66(2):601-4

School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Perth 6009, Australia.

View Article and Find Full Text PDF
January 2006

Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.

Hematol Oncol Clin North Am 2005 Dec;19(6):1025-40, v

School of Medicine and Pharmacology, University of Western Australia, 4th Floor, G-Block, Sir Charles Gairdner Hospital, Nedlands 6009, Western Australia, Australia.

View Article and Find Full Text PDF
December 2005

Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors.

Cancer Immunol Immunother 2006 Aug 11;55(8):933-47. Epub 2005 Nov 11.

School of Medicine and Pharmacology, University of Western Australia, 4th Floor, G Block, Queen Elizabeth II Medical Centre, Perth, WA 6009, Australia.

View Article and Find Full Text PDF
August 2006

Advances in malignant mesothelioma.

N Engl J Med 2005 Oct;353(15):1591-603

School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Nedlands, Perth, Australia.

View Article and Find Full Text PDF
October 2005

Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy.

Cancer Res 2005 Sep;65(17):7580-4

School of Medicine and Pharmacology and Western Australian Institute for Medical Research, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Perth, Australia.

View Article and Find Full Text PDF
September 2005

Malignant mesothelioma.

Lancet 2005 Jul 30-Aug 5;366(9483):397-408

Tumour Immunology Group, School of Medicine and Pharmacology, University of Western Australia, Australia.

View Article and Find Full Text PDF
October 2005

Gene therapy of mesothelioma.

Expert Opin Biol Ther 2005 Aug;5(8):1039-49

Curtin University, School of Biomedical Sciences, Kent St, Bentley, Western Australia, 6102 Australia.

View Article and Find Full Text PDF
August 2005

Soluble mesothelin-related protein--a blood test for mesothelioma.

Lung Cancer 2005 Jul;49 Suppl 1:S109-11

University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Perth, WA, Australia.

View Article and Find Full Text PDF
July 2005

Combining immunotherapy with chemotherapy to treat cancer.

Discov Med 2005 Jun;5(27):265-70

Tumour Immunology Group, School of Medicine and Pharmacology, Western Australian Institute for Medical Research, Perth, 6009, Australia.

View Article and Find Full Text PDF
June 2005

Immunotherapy and chemotherapy--a practical partnership.

Nat Rev Cancer 2005 05;5(5):397-405

Tumour Immunology Group, School of Medicine and Pharmacology, Western Australian Institute for Medical Research, Perth, 6009, Australia.

View Article and Find Full Text PDF
May 2005

Climbing Mount Kilimanjaro in a blizzard.

Med J Aust 2004 Dec 6-20;181(11-12):646-8

School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, WA.

View Article and Find Full Text PDF
March 2005

Current chemotherapeutic treatment of malignant pleural mesothelioma.

Expert Opin Pharmacother 2004 Dec;5(12):2441-9

University of Western Australia, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia.

View Article and Find Full Text PDF
December 2004

CD4+ T cells cross-compete for MHC class II-restricted peptide antigen complexes on the surface of antigen presenting cells.

Immunol Cell Biol 2004 Apr;82(2):103-11

Dame Roma Mitchell Cancer Research Laboratories, Hanson Institute, and Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia.

View Article and Find Full Text PDF
April 2004

Mesothelin-family proteins and diagnosis of mesothelioma.

Lancet 2003 Nov;362(9396):1612-6

University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Western Australia, Perth, Australia.

View Article and Find Full Text PDF
November 2003

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

Cancer Res 2003 Aug;63(15):4490-6

University Department of Medicine, Western Australian Institute for Medical Research, Queen Elizabeth II Medical Centre, 4th Floor, G Block, Nedlands, Perth, Western Australia 6009.

View Article and Find Full Text PDF
August 2003

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.

J Immunol 2003 May;170(10):4905-13

Tumor Immunology Group, Department of Medicine, University of Western Australia and Western Australian Institute of Medical Research, Perth, Australia.

View Article and Find Full Text PDF
May 2003

Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.

Cancer Res 2002 Apr;62(8):2353-8

Western Australian Institute for Medical Research, University Department of Medicine, Queen Elizabeth II Medical Centre, 4th Floor, G Block, Nedlands, Perth, Western Australia 6009.

View Article and Find Full Text PDF
April 2002

New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.

Semin Oncol 2002 Feb;29(1):82-96

University Department of Medicine, University of Western Australia, Verdun St Nedlands, Australia.

View Article and Find Full Text PDF
February 2002